URB2 expression in patients with gliomas was incorporated with nine clinicopathological variables to generate a risk score, including IDH mutation status, grade, sex, histology, age, radio status, Chemo status, PRS type, and 1p/19q codeletion status. The gene discussed is URB2; the disease is central nervous system cancer.